GAITHERSBURG, Md., May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust Company, N.A., as trustee (Indenture), effective May 10, 2019.
As approved by Novavax’ stockholders at a special meeting held on May 8, 2019, Novavax effected a reverse stock split of its issued and outstanding common stock, par value $0.01 (Common Stock) at a ratio of 1-for-20, effective as of 12:01 a.m. Eastern Time on May 10, 2019 (Reverse Stock Split).
As a result of the Reverse Stock Split and pursuant to Section 14.04(a) of the Indenture, effective May 10, 2019, the conversation rate under the Indenture will be equal to 7.3411 shares of Common Stock per $1,000 principal amount of the Convertible Notes.
As a result of the foregoing adjustment to the conversion rate and pursuant to Section 14.03(d) of the Indenture, effective May 10, 2019, the table setting forth the number of additional shares of Common Stock to be added to the conversion rate for each $1,000 principal amount of Notes in connection with a make-whole adjustment event based on hypothetical stock prices and effective dates pursuant to Section 14.03(e) of the Indenture was adjusted to read as follows:
| Stock Price | |||||||||||||||||||||||||||||||||
| Effective Date | $ | 111.20 | $ | 120.00 | $ | 130.00 | $ | 136.20 | $ | 140.00 | $ | 160.00 | $ | 200.00 | $ | 300.00 | $ | 400.00 | $ | 500.00 | $ | 600.00 | |||||||||||
| January 29, 2016 | 1.6517 | 1.5755 | 1.3668 | 1.2563 | 1.1952 | 0.9315 | 0.5983 | 0.2342 | 0.0979 | 0.0373 | 0.0093 | ||||||||||||||||||||||
| February 1, 2017 | 1.6517 | 1.6068 | 1.3859 | 1.2695 | 1.2053 | 0.9302 | 0.5881 | 0.2242 | 0.0918 | 0.0341 | 0.0079 | ||||||||||||||||||||||
| February 1, 2018 | 1.6517 | 1.6198 | 1.3862 | 1.2639 | 1.1967 | 0.9113 | 0.5636 | 0.2069 | 0.0823 | 0.0292 | 0.0057 | ||||||||||||||||||||||
| February 1, 2019 | 1.6517 | 1.6311 | 1.3803 | 1.2501 | 1.1789 | 0.8802 | 0.5267 | 0.1830 | 0.0697 | 0.0231 | 0.0032 | ||||||||||||||||||||||
| February 1, 2020 | 1.6517 | 1.6055 | 1.3357 | 1.1972 | 1.1221 | 0.8124 | 0.4616 | 0.1478 | 0.0530 | 0.0156 | 0.0007 | ||||||||||||||||||||||
| February 1, 2021 | 1.6517 | 1.5419 | 1.2458 | 1.0966 | 1.0167 | 0.6962 | 0.3602 | 0.1017 | 0.0341 | 0.0081 | 0.0000 | ||||||||||||||||||||||
| February 1, 2022 | 1.6517 | 1.3911 | 1.0532 | 0.8889 | 0.8030 | 0.4796 | 0.1974 | 0.0475 | 0.0157 | 0.0019 | 0.0000 | ||||||||||||||||||||||
| February 1, 2023 | 1.6517 | 0.9923 | 0.3512 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||||||||||||||||||
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors:
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
John.woolford@westwicke.com
443-213-0506